Logo image
Epilepsy, atherosclerosis, myocardial infarction, and carbamazepine
Journal article   Peer reviewed

Epilepsy, atherosclerosis, myocardial infarction, and carbamazepine

Jean-Pierre de Chadarévian, Agustin Legido, Daniel K Miles and Christos D Katsetos
Journal of child neurology, v 18(2)
Feb 2003
PMID: 12693787

Abstract

Anticonvulsants - administration & dosage Anticonvulsants - adverse effects Anticonvulsants - therapeutic use Autopsy Carbamazepine - administration & dosage Carbamazepine - adverse effects Carbamazepine - therapeutic use Child Coronary Artery Disease - chemically induced Epilepsy - drug therapy Fatal Outcome Humans Male Myocardial Infarction - chemically induced Renal Insufficiency Rhabdomyolysis - pathology Time Factors
Epileptic patients receiving medications such as phenytoin or phenobarbital have been noted to have an exceedingly low incidence of myocardial infarction, but children treated with carbamazepine have shown alteration of their serum lipid profile that could predispose them to atherosclerosis. This report seems to corroborate this point and describes the findings in an 11-year-old boy who died following a major seizure, rhabdomyolysis, and renal failure. The autopsy demonstrated that he had marked coronary atherosclerosis and myocardial infarction. The child had been treated with carbamazepine for more than 10 years.

Metrics

6 Record Views
25 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Clinical Neurology
Pediatrics
Logo image